[Superior Vena Cava Syndrome and Trousseau Syndrome in a Patient with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin : A Case Report].
{"title":"[Superior Vena Cava Syndrome and Trousseau Syndrome in a Patient with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin : A Case Report].","authors":"Takuya Hida, Naoko Fujita, Takaya Murashima, Masato Fujii, Takahiro Nagai, Chie Onizuka, Koshiro Nishimoto, Atsuro Sawada, Shoichiro Mukai, Toshiyuki Kamoto","doi":"10.14989/ActaUrolJap_71_6_191","DOIUrl":null,"url":null,"abstract":"<p><p>We report a case of superior vena cava syndrome and trousseau syndrome in a patient with metastatic urothelial carcinoma treated with enfortumab vedotin. The patient was a 59-year-old woman diagnosed with left renal pelvic cancer with multiple lymph node metastases and liver metastasis. Treatment with gemcitabine and cisplatin reduced the size of the local tumor but resulted in liver metastasis progression after three cycles. The patient was switched to pembrolizumab which resulted in rapid tumor growth causing superior vena cava syndrome and trousseau syndrome. Hyper-progression was suspected and the patient was immediately switched to enfortumab vedotin. After enfortumab vedotin therapy, the tumor and multiple metastases shrank significantly and tumor reduction was maintained.</p>","PeriodicalId":39291,"journal":{"name":"Acta Urologica Japonica","volume":"71 6","pages":"191-195"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Urologica Japonica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14989/ActaUrolJap_71_6_191","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
We report a case of superior vena cava syndrome and trousseau syndrome in a patient with metastatic urothelial carcinoma treated with enfortumab vedotin. The patient was a 59-year-old woman diagnosed with left renal pelvic cancer with multiple lymph node metastases and liver metastasis. Treatment with gemcitabine and cisplatin reduced the size of the local tumor but resulted in liver metastasis progression after three cycles. The patient was switched to pembrolizumab which resulted in rapid tumor growth causing superior vena cava syndrome and trousseau syndrome. Hyper-progression was suspected and the patient was immediately switched to enfortumab vedotin. After enfortumab vedotin therapy, the tumor and multiple metastases shrank significantly and tumor reduction was maintained.